Co-expression of RON and MET in Bladder Cancer
Author Information
Author(s): Cheng H-L, Liu H-S, Lin Y-J, Chen H H-W, Hsu P-Y, Chang T-Y, Ho C-L, Tzai T-S, Chow N-H
Primary Institution: National Cheng Kung University
Hypothesis
Is co-expression of RON and MET a prognostic indicator for patients with transitional-cell carcinoma of the bladder?
Conclusion
The study found that co-expression of RON and MET is significantly associated with decreased overall survival in bladder cancer patients.
Supporting Evidence
- RON was overexpressed in 32.8% of primary tumours.
- Co-expressed RON and MET was significantly associated with decreased overall survival.
- Overexpression of RON was positively associated with histological grading and larger tumour size.
Takeaway
This study shows that when two proteins, RON and MET, are both present in bladder cancer, it can mean the cancer is more aggressive and patients might need more treatment.
Methodology
The study analyzed RON and MET expression in bladder cancer tissues and evaluated their association with clinical outcomes.
Limitations
The study excluded patients with carcinoma in situ, which may limit the generalizability of the findings.
Participant Demographics
The cohort included 183 patients (117 men and 66 women) aged 23 to 93 years, with a mean age of 64.2 years.
Statistical Information
P-Value
P=0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website